GlassScriptPhysician profile
Abdallah Altarshan
NPI 1174582811
$131,794.51
in general payments reported to CMS, 2019-2025
76 companies · $15K in 2025
The $15K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $17K · 2021: $15K · 2022: $18K · 2023: $8,087 · 2024: $12K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $9,542 · Travel and Lodging: $1,036 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,282.44 |
| Food and Beverage | $9,542.25 |
| Travel and Lodging | $1,036.34 |
| Education | $182.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $83,246.63 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Janssen Pharmaceuticals, INC | $30,405.59 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $3,535.19 | 2019-2025 | |
| Insulet Corporation | $1,368.82 | 2019-2025 | Omnipod |
| Mannkind Corporation | $1,135.52 | 2019-2025 | Afrezza |
| Abbott Laboratories | $1,046.30 | 2019-2025 | Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $1,030.18 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $904.21 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $880.74 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $876.97 | 2019-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $830.18 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Xeris Pharmaceuticals, INC. | $635.68 | 2021-2025 | Recorlev |
| Amgen INC. | $472.61 | 2019-2025 | Tepezza, Repatha, Otezla |
| Preventric Diagnostics, INC. | $394.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $358.31 | 2022-2025 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Altarshan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.